1.51BMarket Cap-10299P/E (TTM)
16.930High15.985Low676.05KVolume16.060Open15.940Pre Close11.05MTurnover1.30%Turnover RatioLossP/E (Static)93.41MShares20.69052wk High4.74P/B841.35MFloat Cap5.12052wk Low--Dividend TTM52.03MShs Float40.490Historical High--Div YieldTTM5.93%Amplitude5.120Historical Low16.351Avg Price1Lot Size
Edgewise Therapeutics Stock Forum
NEWS
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)
Positive two-year topline results from the ARCH trial show stabilization of NSAA scores with sevasemten treatment in adults with Becker Muscular Dystrophy.
Significant decreases in muscle damage biomarkers CK and TNNI2 were observed in participants treated with sevasemten.
Sevasemten was...
Any more news?
when is the fda case?
No comment yet